This study, called NeoPlaTT, is for extremely preterm infants (born between 23 and 26 weeks of pregnancy) who are less than 48 hours old. It aims to find the best level of platelets (tiny blood cells that help stop bleeding) for these babies. Infants will be randomly assigned to one of two groups: a 'Higher Platelet Transfusion Threshold' group or a 'Lower Platelet Transfusion Threshold' group. The study will compare whether a lower platelet threshold improves a baby's survival without major or severe bleeding. The main goal is to see if babies in the lower threshold group have better outcomes up to 40 weeks postmenstrual age (which is how old the baby would be if they were still in the womb). The study is currently recruiting 2433 infants.

Study design

This is a randomized trial where infants are assigned by chance to one of two treatment groups. There will be 2433 participants in total.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed until 40 0/7 weeks postmenstrual age, death, discharge, or transfer outside of the study center, whichever happens first (an average of 98 days postnatal age).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.